Andrew Elliott Place, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2024 | 1547 | 2.510 |
Why?
|
| Asparaginase | 8 | 2024 | 240 | 1.470 |
Why?
|
| Bacillus | 1 | 2018 | 78 | 0.620 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 381 | 0.620 |
Why?
|
| Cataract | 1 | 2022 | 827 | 0.510 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 1189 | 0.470 |
Why?
|
| Oleanolic Acid | 6 | 2005 | 42 | 0.470 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1890 | 0.470 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1171 | 0.450 |
Why?
|
| Neutropenia | 1 | 2018 | 884 | 0.440 |
Why?
|
| Lymphoma | 4 | 2024 | 1896 | 0.410 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1436 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11709 | 0.390 |
Why?
|
| Bacteremia | 1 | 2018 | 980 | 0.390 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 13591 | 0.350 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1065 | 0.310 |
Why?
|
| Leukemia | 3 | 2024 | 1519 | 0.310 |
Why?
|
| Sulfonamides | 1 | 2018 | 1973 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 223 | 0.300 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 1007 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9273 | 0.260 |
Why?
|
| Torque teno virus | 1 | 2024 | 13 | 0.230 |
Why?
|
| Child | 23 | 2024 | 79818 | 0.230 |
Why?
|
| Disease-Free Survival | 5 | 2023 | 6821 | 0.220 |
Why?
|
| Imidazoles | 3 | 2005 | 1179 | 0.220 |
Why?
|
| Escherichia coli | 1 | 2015 | 4215 | 0.220 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2024 | 251 | 0.220 |
Why?
|
| Adolescent | 17 | 2024 | 87892 | 0.200 |
Why?
|
| Infant | 11 | 2022 | 36055 | 0.200 |
Why?
|
| Child, Preschool | 12 | 2021 | 42062 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2022 | 3599 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5649 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2022 | 229 | 0.170 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 126 | 0.170 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 646 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 3840 | 0.160 |
Why?
|
| Remission Induction | 3 | 2020 | 2388 | 0.160 |
Why?
|
| Galectins | 1 | 2021 | 282 | 0.150 |
Why?
|
| Cholecalciferol | 1 | 2003 | 549 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2057 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2021 | 362 | 0.150 |
Why?
|
| Vancomycin | 1 | 2020 | 503 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2016 | 4087 | 0.140 |
Why?
|
| Age Factors | 4 | 2018 | 18358 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 1594 | 0.130 |
Why?
|
| Vincristine | 1 | 2018 | 1038 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 876 | 0.130 |
Why?
|
| Neoplasms | 4 | 2020 | 22032 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3574 | 0.120 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 414 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 553 | 0.120 |
Why?
|
| Young Adult | 11 | 2024 | 58808 | 0.110 |
Why?
|
| Humans | 39 | 2024 | 758406 | 0.110 |
Why?
|
| Prednisone | 1 | 2018 | 1565 | 0.110 |
Why?
|
| Purines | 1 | 2016 | 605 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1346 | 0.110 |
Why?
|
| Orthopedics | 1 | 2022 | 892 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 685 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 555 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2016 | 564 | 0.100 |
Why?
|
| Prognosis | 5 | 2022 | 29557 | 0.100 |
Why?
|
| Triterpenes | 2 | 2003 | 74 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 1855 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2018 | 2209 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2022 | 64378 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10748 | 0.090 |
Why?
|
| U937 Cells | 4 | 2005 | 262 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9404 | 0.090 |
Why?
|
| Canada | 1 | 2015 | 2111 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 7985 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2379 | 0.090 |
Why?
|
| Male | 16 | 2024 | 358747 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 392 | 0.080 |
Why?
|
| Female | 18 | 2024 | 390323 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 21017 | 0.080 |
Why?
|
| Quality of Life | 2 | 2023 | 13285 | 0.080 |
Why?
|
| Adult | 11 | 2024 | 219935 | 0.080 |
Why?
|
| Incidence | 3 | 2024 | 21272 | 0.070 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 489 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 80168 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2003 | 506 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5249 | 0.070 |
Why?
|
| Research Design | 3 | 2018 | 6157 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12440 | 0.060 |
Why?
|
| Recurrence | 1 | 2018 | 8426 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 3 | 2003 | 906 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 851 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6493 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 167 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2005 | 2860 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 1999 | 1245 | 0.060 |
Why?
|
| Leukocytes | 1 | 2011 | 2025 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 296 | 0.050 |
Why?
|
| Terpenes | 1 | 2003 | 96 | 0.050 |
Why?
|
| Cytarabine | 2 | 2022 | 696 | 0.050 |
Why?
|
| Methyl Methanesulfonate | 2 | 1999 | 28 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 462 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7403 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 367 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5629 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2312 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2003 | 610 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4901 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 13468 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 16886 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3615 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1999 | 2416 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2023 | 10171 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3664 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 350 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 39872 | 0.040 |
Why?
|
| United States | 4 | 2024 | 72136 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 855 | 0.040 |
Why?
|
| Cell Division | 2 | 2003 | 4458 | 0.040 |
Why?
|
| Pediatrics | 1 | 2013 | 3587 | 0.040 |
Why?
|
| Cell Separation | 1 | 2003 | 1720 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 635 | 0.040 |
Why?
|
| Animals | 10 | 2023 | 167768 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 10146 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2016 | 1745 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2796 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5790 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1752 | 0.040 |
Why?
|
| Caspases | 1 | 2000 | 876 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2000 | 695 | 0.030 |
Why?
|
| Nitriles | 1 | 2002 | 957 | 0.030 |
Why?
|
| Mice | 8 | 2023 | 81101 | 0.030 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 231 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 9574 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 23884 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12721 | 0.030 |
Why?
|
| Risk Factors | 3 | 2024 | 73809 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4738 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 640 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1613 | 0.030 |
Why?
|
| Azacitidine | 1 | 2018 | 334 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1542 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 1404 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 300 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39059 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 1958 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 352 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 677 | 0.030 |
Why?
|
| Monocytes | 1 | 2003 | 2570 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 367 | 0.030 |
Why?
|
| Dexamethasone | 2 | 2016 | 1927 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 712 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6127 | 0.030 |
Why?
|
| Mutation | 3 | 2023 | 29915 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1705 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2002 | 2131 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5864 | 0.030 |
Why?
|
| Patient Selection | 1 | 2024 | 4244 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2411 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2013 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1999 | 1801 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1825 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2385 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2018 | 1268 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2003 | 11471 | 0.020 |
Why?
|
| Macrophages | 2 | 2003 | 5737 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5199 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2018 | 3991 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 1999 | 87 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 2269 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 219568 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5065 | 0.020 |
Why?
|
| bcl-X Protein | 2 | 2000 | 411 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2018 | 2909 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2533 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2003 | 12094 | 0.020 |
Why?
|
| Phosphorylation | 3 | 2005 | 8297 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1855 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2023 | 12876 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2511 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10112 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 54137 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 451 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12096 | 0.010 |
Why?
|
| Transfection | 2 | 2005 | 5779 | 0.010 |
Why?
|
| Isoenzymes | 2 | 1999 | 1686 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 9468 | 0.010 |
Why?
|
| Forecasting | 1 | 2013 | 2923 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3609 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 308 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3082 | 0.010 |
Why?
|
| Mink | 1 | 2003 | 31 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 10718 | 0.010 |
Why?
|
| Smad7 Protein | 1 | 2003 | 40 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1999 | 3593 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2003 | 145 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 490 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 363 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 5779 | 0.010 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2005 | 374 | 0.010 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2003 | 150 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 278 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2003 | 231 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 301 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12870 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1455 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 337 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 185 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 237 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 189 | 0.010 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 20 | 0.010 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 1999 | 20 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 168218 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2000 | 363 | 0.010 |
Why?
|
| Vanadates | 1 | 1999 | 82 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 607 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1999 | 317 | 0.010 |
Why?
|
| Signal Transduction | 4 | 2005 | 23342 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 1999 | 114 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 455 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16534 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 660 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41256 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1999 | 318 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 728 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 1866 | 0.010 |
Why?
|
| Serpins | 1 | 1999 | 247 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 441 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1084 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 1662 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1999 | 425 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 459 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 3069 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 638 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 597 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 685 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7843 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1199 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 3099 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 1076 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 3156 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1645 | 0.010 |
Why?
|
| Rats | 2 | 1999 | 23679 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1999 | 1398 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3442 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 12759 | 0.000 |
Why?
|
| Cell Line | 1 | 1999 | 15591 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9985 | 0.000 |
Why?
|